within Pharmacolibrary.Drugs.ATC.R;

model R01AD57
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Tixocortol is a corticosteroid with minimal systemic glucocorticoid effect, typically used topically for its anti-inflammatory and anti-allergic properties. In combination products, it is used for local treatment of nasal inflammatory conditions such as rhinitis. Tixocortol is not widely used or approved in most countries today; nasal formulations are largely historical.</p><h4>Pharmacokinetics</h4><p>There are no published studies directly reporting pharmacokinetic parameters for tixocortol in combination products administered via the nasal route in humans.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R01AD57;
